- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06493084
Evaluar LAE102 en sujetos sanos y sujetos con sobrepeso y obesidad
Un estudio de fase I aleatorizado, doble ciego, controlado con placebo, de aumento de dosis única y múltiple para evaluar la seguridad, tolerabilidad y farmacocinética de LAE102 en sujetos sanos y sujetos con sobrepeso u obesidad
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of LAE102 injection in healthy and overweight/obese participants, and also evaluate the preliminary pharmacodynamic effect of multiple dose injections in overweight/obese participants.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Part A is a randomized, double-blinded, placebo-controlled, single ascending dose by Intravenous (IV) administration in 40 Healthy participants;
Part B is a randomized, double-blinded, placebo-controlled, single ascending dose by subcutaneous (SC) administration in 24 Healthy participants;
Part C is a randomized, double-blind, placebo-controlled, multiple dose ascending and expanding by subcutaneous (SC) administration in 60 overweight/obese participants.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Porcelana, 201203
- Fudan Zhongshan Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female and aged 18 to 65 years (inclusive) at the screening visit
- Male Body weight ≥ 50 kg, female Body weight ≥ 45 kg. For Part A&B, 18.5 ≤ BMI ≤ 28 kg/m². For part C, 26.0 ≤ BMI ≤ 40.0 kg/m²
- Negative for human immunodeficiency virus antibody (HIV-Ab).
- Female subjects with no childbearing potential or with childbearing potential which serum human chorionic gonadotropin (hCG) test must <5mIU/mL .
- Male subjects are not allowed to donate sperm during this trial.
- Voluntarily participate in the study and provide a signed and dated informed consent form.
- Willing to comply with the scheduled visits, study treatment, laboratory tests, and other study-related procedures and requirements as stipulated in the study protocol.
Exclusion Criteria:
- With clinically significant abnormalities in vital signs, physical examination, ECG or laboratory test results specified in the protocol.
- Allergy to the investigational drug or its excipients, or a history of severe allergy (including any food or drug allergies).
- Self-reported weight change is more than 5% in the previous 3 months prior to screening.
- Diagnosed with secondary overweight or obesity.
- Any clinically significant medical conditions and any diseases affecting the safety of the subject or the determination of study results.
- History of major diseases or physical conditions in the central nervous system, respiratory system, cardiovascular system, digestive system, blood system, endocrine system, musculoskeletal diseases, mental illness, urinary system, or tumors, or any existing acute diseases, or other diseases or physical conditions that may affect the study or pose an unacceptable risk to the subjects.
- Positive for hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCV-Ab), or syphilis spirochete antibody (TP-Ab).
- Known or suspected history of substance abuse or positive drug screening test.
- Alcohol abuse within 1 year before screening or positive alcohol breath test at baseline.
- Smoking more than 5 cigarettes per day within 3 months before screening, or unable to comply with the prohibition of smoking during the study period.
- Received any vaccine within 30 days prior to screening, or planned to receive any vaccine during the study period.
- Inability to ensure no use of any drugs, including prescription and non-prescription drugs (excluding paracetamol, ibuprofen, and topically applied eye/nasal drops and ointments with no systemic exposure risk), vitamins, supplements and herbal medicines, from 14 days before the initial administration (if the half-life of the drug used exceeds 14 days, then 5 half-lives shall apply) until the last visit period.
- Participated in any clinical trial and received an investigational medicine or medical device within 3 months prior to dosing of the investigational product.
- Underwent major surgery within 30 days before the initial administration or planned to undergo major surgery during the study period.
- Donated blood or experienced blood loss ≥400 mL within 3 months before screening or received a blood transfusion.
- Have special dietary requirements and cannot comply with a standardized diet.
- History of fainting or syncope.
- Dieting or receiving weight loss treatment within 30 days before the initial administration or experiencing major changes in lifestyle.
- Use of GLP-1 receptor agonists, or weight loss medications or systemic corticosteroids (oral or intravenous for more than 7 days), or psychiatric medications within 3 months prior to the initial administration. Applicable to part C.
- Regular engaged in muscle strength related exercise, applicable to part C.
- Other situation that the investigator considers not appropriate.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Part A LAE102 IV
Single dose LAE102 by IV administration |
A single dose of LAE102 administered intravenously
Otros nombres:
|
|
Comparador de placebos: Part A placebo IV
Single dose placebo by IV administration |
A single dose of placebo administered intravenously
Otros nombres:
|
|
Experimental: Part B LAE102 SC
Single dose LAE102 by SC administration |
Single dose of LAE102 administered subcutaneously
Otros nombres:
|
|
Comparador de placebos: Part B placebo SC
Single dose placebo by SC administration |
single dose of placebo administered subcutaneously
Otros nombres:
|
|
Experimental: Part C LAE102 SC
Multiple dose LAE102 by SC administration |
Multiple dose of LAE102 administered subcutaneously
Otros nombres:
|
|
Comparador de placebos: Part C placebo SC
Multiple dose placebo by SC administration |
Multiple dose of placebo administered subcutaneously
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number & severity of participants with treatment-related adverse events as assessed by CTCAE V5.0
Periodo de tiempo: From Day 1 to Day 29 for single dose part. From Day 1 to Day 196 for multiple dose part
|
Findings on physical examination, ECG, vital signs, and reports of the laboratory results based on the CTCAE v5.0 |
From Day 1 to Day 29 for single dose part. From Day 1 to Day 196 for multiple dose part
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
characterize the peak of serum concentration (Cmax) of LAE102 injection in healthy subjects
Periodo de tiempo: From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
For both intravenously guttae & subcutaneous injection, to evaluate the maximum observed serum concentration(Cmax) |
From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
|
characterize the area under the serum concentration versus time curve (AUC) of LAE102 injection in healthy subjects
Periodo de tiempo: From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
For both intravenously guttae & subcutaneous injection, to evaluate the area under the serum concentration versus time curve (AUC) |
From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
|
evaluate the expression levels of Activin A in blood samples
Periodo de tiempo: From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
The validated methodology was employed to assay serum levels of Activin A in biological samples. |
From pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
|
Incidence of positive Anti-drug antibody(ADA) after administration
Periodo de tiempo: pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
Test ADA status in biological sample via validated methodology |
pre-dose to Day 29 for single dose part. From pre-dose to Day 196 for multiple dose part.
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Preliminary pharmacodynamic of total body weight for multiple dose part
Periodo de tiempo: From pre-dose to Day 168.
|
Changes and percentage changes in total body weight (kg) after administration |
From pre-dose to Day 168.
|
|
Preliminary pharmacodynamic of lean mass for multiple dose part
Periodo de tiempo: From pre-dose to Day 168.
|
Changes and percentage changes in lean mass after administration |
From pre-dose to Day 168.
|
|
Preliminary pharmacodynamic of fat mass for multiple dose part
Periodo de tiempo: From pre-dose to Day 168.
|
Changes and percentage changes in fat mass after administration |
From pre-dose to Day 168.
|
|
Preliminary pharmacodynamic of thigh muscle volume for multiple dose part
Periodo de tiempo: From pre-dose to Day 168
|
Changes and percentage changes in thigh muscle volume after administration |
From pre-dose to Day 168
|
|
Preliminary pharmacodynamic of bone mineral density(BMD) for multiple dose part
Periodo de tiempo: From pre-dose to Day 168
|
Changes and percentage changes in BMD after administration |
From pre-dose to Day 168
|
|
BMI/waist circumference change and percentage.
Periodo de tiempo: From pre-dose to Day 29 forsingle dose. From pre-dose to Day 196 for multiple dose.
|
Assess the Body Mass Index (BMI)/waist circumference change and percentage. |
From pre-dose to Day 29 forsingle dose. From pre-dose to Day 196 for multiple dose.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Xuening Li, Professor, Zhongshan hospital affiliated to Fundan University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- LAE102CN1001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .